Nothing to See Here

The Map

The Lyme disease argument keeps returning to a map.

Lyme, Connecticut sits on the eastern side of the Connecticut River. Across Long Island Sound sits Plum Island, a restricted federal disease-research site with a long animal-disease mission and a short Cold War military chapter. One place gave the illness its public name. The other place gave suspicion a fixed address. The water carries no proof by itself. It carries the reason suspicion keeps returning.

Robert F. Kennedy Jr. supplies the news trigger. The subject is the public record. In a December 15, 2025 HHS roundtable announcement , the department said Lyme patients had been denied accurate diagnostics and meaningful care for decades, renewed the LymeX diagnostic effort, and described an illness affecting millions of Americans. HHS also said current tests often miss early or late-stage infection and that persistent symptoms affect up to 20 percent of patients. That language carries force because it comes out of the federal world that patients spent years trying to persuade.

Public authority stays testable even when it changes tone. Kennedy’s intervention should open the file, not close it. The proper question is larger than any single official: how did a real, common, sometimes disabling disease become so procedurally hard to believe?

The answer begins with the record itself.

The First Witnesses

Lyme entered modern public medicine through parents before it entered through agencies.

In 1975, Judith Mensch heard about children around Lyme, Connecticut with arthritis-like illness. When her own daughter’s knee swelled so badly she could barely walk, Mensch rejected the juvenile-arthritis explanation and gathered names. Polly Murray, a few miles away, had seen illness in her own family and neighbors. The state brought in Yale physicians Allen Steere and Stephen Malawista, who surveyed Lyme, Old Lyme, and East Haddam and found 51 cases with similar symptoms, many near wooded areas, often appearing in summer or early fall. Yale’s own history of the discovery now describes that patient-driven origin and the later identification of the bacterium Borrelia burgdorferi.

That origin anchors the story. Lyme disease entered the official account because ordinary people refused a story that did not match the bodies in front of them.

The same pattern kept reappearing. Patients saw collapse before forms counted disease. Families saw disability before case definitions made room for it. Clinicians who treated complex cases often learned the limits of the script before agencies revised public language. The record did move, but it moved late and in pieces.

The disease was named after a place, but the bacterium was old. Yale researchers later reported genomic evidence that B. burgdorferi had circulated in North America for at least 60,000 years. Their account ties the modern epidemic to ecological change: forest fragmentation, suburbanization, deer, ticks, and habitat conditions that made transmission easier.

That older history undercuts a simple laboratory-origin story for Lyme disease. It also makes the public-health failure more legible. The pathogen had a deep natural history. The modern record was the human system that failed to see it cleanly.

The Count That Shrunk the Disease

Surveillance and burden were never the same thing.

For years, the public picture of Lyme disease leaned on reported-case counts, while the actual number of diagnosed and treated patients was far larger. A CDC Emerging Infectious Diseases claims analysis by Kugeler and coauthors estimated that about 476,000 Americans received a Lyme disease diagnosis each year during 2010-2018. The paper was careful about what it measured: the societal and clinical burden of people diagnosed and treated, a different question than exact infections.

That distinction should have shaped public language. Instead, reported cases became shorthand for disease size. A surveillance tool, useful for tracking trends, narrowed the public imagination.

HHS now repeats the 476,000-per-year figure on its Lyme page and pairs it with another admission: current diagnostics cannot yet reliably detect all stages of Lyme disease. It also says many patients continue to experience persistent symptoms after antibiotics and that the economic burden remains incompletely measured because research and data are limited.

Those are not fringe claims. They are federal claims.

The minimization did not require one secret memo. It worked through categories. Reported cases stood in for burden. Surveillance criteria drifted into clinical thinking. A negative or mistimed test became evidence against the patient instead of evidence of diagnostic limits. The person with the wrong rash, wrong timing, wrong geography, wrong lab result, or lingering symptoms became inconvenient to the clean paragraph.

A disease can be hidden in public by being mismeasured.

The Test at the Door

The testing problem became one of the central failures.

HHS says current diagnostics cannot reliably detect every stage of Lyme disease. That sentence changes how decades of dismissal should be read. A weak diagnostic system cannot act like a perfect gatekeeper for belief.

Many patients experienced exactly that gatekeeping. They arrived sick. The test came back negative, unclear, late, or mismatched to the stage of illness. The chart converted uncertainty into exclusion. The body stayed sick after the record moved on.

The federal Tick-Borne Disease Working Group’s access-to-care material describes the structural problem directly. The report warns that surveillance case criteria are epidemiologic tools and are not intended to identify all actual illness. It says using those criteria as diagnostic or research-entry criteria can become a structural determinant of health that perpetuates disparities. It also reports severe barriers for persistent Lyme disease and chronic Lyme disease patients: diagnostic delays, long travel for treatment, difficulty obtaining care, and denial of treatment.

This is where public-record failure becomes ordinary. It lives in a form, cutoff, billing rule, guideline, insurance denial, or research entry screen. The system can avoid saying, “We do not believe you.” It can say, “You do not meet criteria.”

For a patient, that distinction may have no practical difference.

The diagnostic gate can shrink illness before medicine has explained it.

The Body After the Case

The tidy public story was familiar: tick bite, bull’s-eye rash, antibiotics, recovery.

That path exists. It saves people when detection and treatment arrive early. It also left too much out.

The National Academies reported in 2025 that about 10-20 percent of people who contract Lyme disease develop persistent, often debilitating symptoms such as chronic pain, fatigue, and cognitive dysfunction. The same report said there are no validated interventions to treat Lyme infection-associated chronic illnesses.

Johns Hopkins’ Lyme Disease Research Center has pushed against the old psychosomatic shortcut. In 2025, the center summarized peer-reviewed work finding that persistent Lyme-associated symptoms are biologically driven. One Hopkins study found that 14 percent of patients treated early with standard antibiotics developed persistent, functionally impairing symptoms known as post-treatment Lyme disease. Hopkins also points to imaging and clinical research on white-matter changes, dysautonomia, POTS, subtle joint inflammation, immune response, microbiome, metabolome, and gene-regulation patterns.

The mechanisms remain unsettled. Persistent infection, immune dysregulation, tissue damage, co-infections, neurological injury, microbiome change, and treatment response all require careful evidence. The unsettled biology is the reason dismissal was reckless. Failure to explain a condition is not evidence that the patient invented it.

The more honest record says something harder and more useful: Lyme disease is often treatable, delayed care can be life-altering, persistent symptoms are real for a significant minority, and medicine lacks the tools to sort every mechanism cleanly.

The case can close while ordinary life carries the illness.

The Island Across the Sound

Plum Island belongs in the record without turning the essay into a cheap mystery story.

The stronger case is about secrecy, proximity, documents, and disclosure. CT Insider describes Plum Island as a restricted Long Island Sound site used for federal animal-disease research, including dangerous foreign animal diseases such as foot-and-mouth disease and African swine fever. It also describes the 1952-1954 Army Chemical Corps use of Lab 257, a former torpedo storehouse, to study exotic animal diseases for offensive and defensive purposes. The same report says secretive Army operations and destroyed Lab 257 records fed decades of suspicion, while officials maintain that Lyme disease was never studied on Plum Island.

Those facts do not prove that Plum Island caused the Lyme epidemic. They prove that public suspicion has a record behind it.

There was a restricted federal disease site across the Sound from the community where Lyme entered American public medicine. There was a documented Cold War biological-research chapter. Some records tied to Lab 257 were destroyed. Public access was limited for decades. Official denial arrived in a country with a longer history of secret biological and entomological programs.

Trust cannot substitute for a record.

Congress has now reopened part of the tick-weapons question. Rep. Chris Smith’s 2025 press release says an FY2026 defense-bill amendment directs the Government Accountability Office to review Cold War-era federal research dated January 1, 1945 through December 31, 1972 and determine if ticks were used as hosts or delivery mechanisms for biological warfare agents. The review is supposed to include experiments involving Spirochaetales and Rickettsiales, bacterial orders relevant to tick-borne disease.

That review may find no Plum Island link. A clean record after review would matter. Mockery before review does not.

The genomic history also matters. B. burgdorferi predates the modern laboratory era by tens of thousands of years. That evidence makes a simple invented-in-a-lab claim weak. The narrower public questions remain strong: What tick and vector research did federal programs conduct? Which agents were studied? Which records were withheld, destroyed, or left unread? Did official certainty run ahead of the available evidence? Which questions can now be answered through lawful disclosure?

Those questions are public-record work, part of science’s civic boundary.

Ridicule as a Sorting Device

The public learned Lyme through two poor genres.

One was the pamphlet: avoid ticks, watch for a rash, take antibiotics, recover. The other was the gothic story: secret island, strange ticks, hidden lab, fringe doctor, paranoid patient. The pamphlet was too tidy. The gothic story was easy to mock. The sick person often vanished in the space left by both.

That person might have no classic rash, delayed testing, neurological symptoms, heart symptoms, joint pain, crushing fatigue, cognitive dysfunction, co-infections, insurance denial, or a physician worried about professional consequences. A family would watch an ordinary life shrink while public language treated the illness as simple, suspect, or socially embarrassing.

Independent reporting kept the harder reality visible. Lindsay Keys’ film page describes The Quiet Epidemic as a 2022 documentary about chronic Lyme, with festival screenings, theatrical release, and a 2024 Capitol screening. Bay Area Lyme Foundation identifies Kris Newby as author of Bitten: The Secret History of Lyme Disease and Biological Weapons and senior producer of Under Our Skin, both part of the public argument over tick-borne disease history.

Every independent claim needs evidence. The civic value of the work is that it preserved questions the official system narrowed, postponed, or made socially costly to ask.

“Conspiracy theory” became a sorting label. It swept very different claims into one pile: Lyme is serious; surveillance undercounts; testing is limited; persistent illness is real; federal tick and vector research existed; Plum Island had a Cold War military chapter; Plum Island caused Lyme disease. Some of those claims are established. Some are supported and developing. Some remain unresolved. Some may be wrong.

A serious public culture keeps the distinctions clear. A lazy culture laughs at the pile.

The laughter had consequences because it trained readers to suspect the sick body before suspecting the record that failed to hold it.

Kennedy as Trigger

Kennedy’s intervention matters because it moves the argument’s location. Patients and clinicians had argued for years that the official story was too small. HHS is now using language that acknowledges diagnostic limits, persistent illness, millions affected, and the need for new tools.

That does not make Kennedy the referee. It makes the federal record newly unstable in a useful way. Old agency confidence and new political confidence both need scrutiny.

The CDC, NIH, HHS, specialty guidelines, insurance incentives, research designs, medical boards, documentary filmmakers, advocacy groups, and clinicians all belong inside the examination. No single actor should get to decide that its own record is the record. Public trust grows through disclosure, source hierarchy, and correction, not borrowed authority.

Kennedy’s role is valuable if it forces the file open. It becomes dangerous if one form of unquestioned authority merely replaces another.

The stronger path is to return every claim to the record, expand the record where it is too narrow, and stop using uncertainty as a weapon against patients.

The Cover-Up Worth Naming

“Cover-up” is a heavy word. In Lyme disease, the most durable cover-up was often administrative, clinical, financial, and cultural.

It was the undercount that made the disease look smaller.

It was the test that missed too much and then became the gate.

It was the surveillance definition drifting into diagnosis.

It was the research study that excluded the messy patient.

It was the insurer turning uncertainty into nonpayment.

It was the medical board making clinicians fear complex treatment.

It was the pamphlet making recovery sound simpler than many patients experienced.

It was the article that turned chronic Lyme into a cultural type.

It was the public-health voice treating distrust as irrational without asking what produced it.

That is how a disease gets minimized in a country full of agencies, laboratories, journals, hearings, documentaries, foundations, and physicians. The disease is not erased. It is made procedurally unbelievable.

The sick person remains visible to family, employer, school, spouse, child, and mirror. Inside the official record, the person becomes conditional.

Filling the Gaps

A serious Lyme agenda would begin with admission.

Public language should separate surveillance from diagnosis. Early treatment matters. Delayed care can change a life. Persistent Lyme-associated illness is real. Mechanisms under study should be treated as research problems, not patient credibility problems.

Diagnostics need to do more than confirm a narrow clinical picture. They need to detect more stages of disease and help distinguish active infection, past exposure, immune aftermath, co-infection, and related infection-associated chronic illness. Complex patients need clinical centers that can evaluate them without pushing them into denial on one side or miracle-cure markets on the other.

Federal records also need sunlight. Lawful records tied to tick-borne research, Plum Island, Fort Detrick, Dugway, Cold War vector work, and agency communications should be reviewed and released where law allows. Disclosure does not equal guilt. Secrecy does not equal safety.

The map anchors the public question.

Lyme and Old Lyme are places where ordinary people forced the record to notice what bodies already knew. Plum Island is not proof of origin. It is proof that secrecy leaves a wake.

A public record worthy of trust does not ask sick people to disappear into its gaps.

It goes back and fills them.